BENDAMUSTINE HYDROCHLORIDE
Clinical safety rating: avoid
Contraindicated (not allowed)
Bendamustine is a bifunctional mechlorethamine derivative that alkylates and crosslinks DNA, leading to DNA damage, inhibition of DNA synthesis, and apoptosis. It also activates p53-dependent DNA repair stress pathways and induces mitotic catastrophe.
| Metabolism | Primarily hydrolyzed to inactive metabolites (monohydroxy, dihydroxy) via non-enzymatic hydrolysis. Minor metabolism via CYP1A2, but CYP pathways are not clinically significant. No active metabolites. |
| Excretion | Renal: ~50% (mainly as metabolites, <5% unchanged). Biliary/fecal: ~40% as metabolites. Approximately 90% of dose eliminated within 72 hours. |
| Half-life | Terminal half-life: ~40 minutes (unchanged drug); active metabolites (M3, M4): 3-4 hours. Clinical context: short half-life of parent drug necessitates infusion protocol; metabolites accumulate and correlate with myelosuppression. |
| Protein binding | 94-96% bound, primarily to albumin (≈95%) and alpha-1-acid glycoprotein. Binding is concentration-independent. |
| Volume of Distribution | Vd at steady state: 15-20 L/kg (approx. 18 L/kg). Indicates extensive tissue distribution and high extravascular sequestration. |
| Bioavailability | Not applicable (IV only). No oral formulation; oral bioavailability is <1% due to extensive first-pass metabolism. |
| Onset of Action | IV: Clinical effect typically seen within 1-2 days for lymphoreduction; maximal cytoreduction occurs days to weeks after multiple cycles. |
| Duration of Action | Duration of action for lymphodepletion: approximately 4-6 weeks; recovery of lymphocyte count nadir occurs by day 21-28. Clinical notes: immunosuppressive effect persists beyond drug clearance; neutrophil nadir typically day 14-21. |
120 mg/m² intravenously over 60 minutes on days 1 and 2 of each 21-day cycle, for up to 6 cycles (in combination with rituximab for indolent B-cell non-Hodgkin lymphoma). Other regimens exist; refer to specific protocol.
| Dosage form | SOLUTION |
| Renal impairment | Creatinine clearance (CrCl) ≥40 mL/min: No adjustment. CrCl <40 mL/min: Not recommended; insufficient data. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 75% of recommended. Child-Pugh Class C: Avoid use. |
| Pediatric use | Safety and efficacy not established; not approved for pediatric use. |
| Geriatric use | No specific dose adjustment recommended based on age alone; monitor renal function and hematologic toxicity closely due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Inhibitors of CYP1A2 may increase bendamustine exposure Myelosuppression is common monitor blood counts regularly Infusion reactions and skin reactions may occur.
| Breastfeeding | It is unknown if bendamustine is excreted in human breast milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. No M/P ratio is available. |
| Teratogenic Risk | Bendamustine hydrochloride is embryotoxic and teratogenic in animal studies. In humans, it is contraindicated in pregnancy due to risk of fetal harm. First trimester exposure carries highest risk for major malformations. Second and third trimester exposure may cause fetal growth restriction, myelosuppression, and increased risk of preterm birth. |
■ FDA Black Box Warning
Bendamustine hydrochloride can cause myelosuppression, infections, infusion reactions, anaphylaxis, tumor lysis syndrome, skin reactions including Stevens-Johnson syndrome, and secondary malignancies including myelodysplastic syndrome and acute myeloid leukemia.
| Common Effects | Myelosuppression |
| Serious Effects |
["Hypersensitivity to bendamustine or mannitol","Severe renal impairment (CrCl <30 mL/min) – relative","Active infection – relative"]
| Precautions | ["Myelosuppression: monitor blood counts","Infusion reactions: premedicate and monitor","Tumor lysis syndrome: ensure adequate hydration and prophylactic allopurinol","Severe skin reactions: discontinue if severe or progressive","Hepatotoxicity: monitor liver function","Secondary malignancies: risk of MDS/AML","Extravasation injury: avoid extravasation"] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count (CBC) with differential, liver function tests (LFTs), renal function, electrolytes, and uric acid levels before and during therapy. Assess for tumor lysis syndrome and infection. Fetal monitoring: serial ultrasound for growth restriction and anatomy screening if exposure occurs. |
| Fertility Effects | Bendamustine can cause gonadal suppression, amenorrhea, and azoospermia. It may reduce fertility in both males and females. Pre-treatment fertility preservation counseling is recommended. |
| No specific dietary restrictions beyond avoiding grapefruit/grapefruit juice. Maintain adequate hydration (aim for 2-3 liters/day unless contraindicated) to reduce risk of tumor lysis syndrome and nephrotoxicity. Alcohol may increase nausea, dizziness, and hepatotoxicity risk; avoid or limit consumption during treatment. |
| Clinical Pearls | Bendamustine is a bifunctional alkylating agent with unique mechanisms including alkylation and inhibition of mitotic checkpoints. It requires reconstitution with sterile water and further dilution in normal saline (0.9% NaCl) or dextrose 5% in water (D5W); use within 3 hours at room temperature or 24 hours under refrigeration. Premedicate with antiemetics (e.g., ondansetron) and consider prophylaxis for tumor lysis syndrome (allopurinol, hydration) especially in patients with high tumor burden. Infusion reactions are common: slow infusion rate or administer antihistamines/corticosteroids. Monitor complete blood count (CBC) frequently for myelosuppression (nadir at 2-3 weeks). Bendamustine is not interchangeable with other alkylators; hypersensitivity reactions may occur, especially in later cycles. Avoid live vaccines during therapy. |
| Patient Advice | This medication is a chemotherapy drug that works by damaging cancer cell DNA. · Common side effects include nausea, vomiting, fatigue, fever, and lowered blood cell counts (increasing infection and bleeding risk). · Drink plenty of fluids to help prevent kidney problems; report any decrease in urination or swelling. · Do not receive any live vaccines (e.g., flu nasal spray, shingles vaccine) during treatment without consulting your oncologist. · Use effective contraception during treatment and for at least 3 months after stopping. · Avoid grapefruit and grapefruit juice as they may interfere with drug metabolism. · Report any signs of infection (fever, chills), unusual bleeding or bruising, or allergic reactions (rash, hives, difficulty breathing) immediately. · May cause drowsiness or dizziness; avoid driving or operating heavy machinery if affected. |